洛赛克联合思他宁治疗上消化道出血的效果及不良反应观察

摘要
图/表
参考文献(15)
相关文章 (5)

全文: PDF (0 KB) HTML (31 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨在评价洛赛克联合思他宁对于上消化道出血的临床效果和安全性。方法2011年1月～2017年1月，我院消化内科100例上消化道出血患者随机分为观察组和对照组，每组各50例。观察组采用洛赛克联合思他宁治疗；对照组采用洛赛克治疗。同时，两组患者均接受禁食、补液以及止血剂等常规保守治疗。记录和比较两组患者的的住院时间、住院费用、输血量、急诊手术率、3个月未愈率以及不良反应的发生率。结果观察组的住院时间明显低于对照组，差异有统计学意义[（6.78±0.74）d vs.（9.62 ±1.26）d]（P＜0.01）；观察组的住院费用明显低于对照组，差异有统计学意义[（14361.64±3033.71）元 vs.（18225.80±7249.82）元]（P＜0.01）；观察组的输血量明显低于对照组，差异有统计学意义[（2.43±1.55）U vs.（3.36±1.68）U]（P＜0.05）；观察组的急诊手术率明显低于对照组，差异有统计学意义（4.00%vs.10.00%）（P＜0.05）；观察组的3个月未愈率明显低于对照组，差异有统计学意义（4.00%vs.6.00%）（P＜0.05）；两组的不良反应发生率相比较，差异无统计学意义（P＞0.05）。结论洛赛克联合思他宁与洛赛克单用相比较，明显缩短了住院时间，降低了住院费用，减少了输血量，降低了急诊手术率和3个月未愈率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	翁燕丽
	符红波
	周燕琼
	林少梅
	吴少霞

关键词 ：上消化道出血, 洛赛克, 思他宁

Abstract：

ObjectiveTo evaluate the clinical efficacy and safety of Losec combined with Stilamin for upper gastrointestinal bleeding.M ethodsFrom January 2011 to January 2017,100 patients with upper gastrointestinal bleeding were randomly divided into observation group and control group.There were 50 cases in each group.The observation group was treated with Losec combined with Stilamin and the control group was treated with Losec alone.At the same time,two groups of patients were

received：fasting,rehydration and hemostatic agents and other conventional conservative treatment.The hospitalization time,hospitalization cost,blood transfusion,emergency surgery rate,3-month non-cure rate,and adverse events were recorded and compared.ResultsThe hospitalization cost of the observation group was significantly lower than thatof the control group,the differencewas statistically significant[（6.78±0.74）d vs.（9.62 ±1.26）d]（P＜0.01）;the hospitalization cost of the observation group was significantly lower than that of the control group,the difference was statistically significant[（14361.64±3033.71）yuan vs. （18225.80±7249.82）yuan]（P＜0.01）.The blood transfusion in the observation group was significantly lower than that in the control group[（2.43±1.55）U vs.（3.36±1.68）U]（P＜0.05）.The emergency surgery rate in the observation group was significantly lower than that in the controlgroup （4.00%vs.10.00%）（P＜0.05）；The 3-month non-cure rate in the observation group was significantly lower than that in the control group（4.00%vs.6.00%）（P＜0.05）；therewasno significantdifference in the incidenceofadverse reactionsbetween the twogroups(P＞0.05).ConclusionCompared with losecine,the combination of Stilamin and Losec significantly reduced hospital stay,reduced hospitalization costs,reduced blood transfusion,reduced emergency surgery and 3-month non-healing rates.

Key words： Upper gastrointestinal bleeding Losec Stilamin

作者简介: 翁燕丽（1975-），女，广东汕头人，本科，主管药师，研究方向：医院药学

引用本文:

翁燕丽;符红波;周燕琼;林少梅;吴少霞. 洛赛克联合思他宁治疗上消化道出血的效果及不良反应观察[J]. 中国当代医药, 2017, 24(22): 132-134.
WENG Yan-li;FU Hong-bo;ZHOU Yan-qiong;LIN Shao-mei;WU Shao-xia. Efficacy and adverse reactions of Losec and Stilam in in the treatment of upper gastrointestinal bleeding. 中国当代医药, 2017, 24(22): 132-134.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I22/132

[1]	Lanas-Gimeno A，Lanas A.Risk of gastrointestinal bleeding during anticoagulant treatment[J].Expert Opin Drug Saf，2017，16（6）：673-685.
[2]	Guo X，Wei J，Gao L，et al.Hyperammonemic coma after craniotomy：Hepatic encephalopathy from uppergastrointestinal hemorrhage or valproate side effect？Case reportand literature review[J].Medicine（Baltimore），2017，96（15）：e6588.
[14]	Naut ER.The approach to occult gastrointestinal bleed[J].Med Clin North Am，2016，100（5）：1047-1056.
[3]	Ray DM，Srinivasan I，Tang SJ，et al.Complementary roles of interventional radiology and therapeutic endoscopy in gastroenterology[J].World JRadiol，2017，9（3）：97-111.
[4]	Ghassemi KA，Jensen DM.What does lesion blood flow tell us about risk stratification and successful management of non-varicealUGIBleeding？[J]CurrGastroenterolRep，2017，19（4）：17.
[5]	Lavie CJ，Howden CW，Scheiman J，Tursi J.Upper gastrointestinal toxicity associated with long-term aspirin therapy：consequences and prevention[J].Curr Probl Cardiol，2017，42（5）：146-164.
[6]	Hakim S，Bortman J，Orosey M，et al.Case report and systematic literature review of a novel etiology of sinistral portal hypertension presenting with UGI bleeding：Left gastric artery pseudoaneurysm compressing the splenic vein treated by embolization of the pseudoaneurysm[J].Medicine（Baltimore），2017，96（13）：e6413.
[7]	Romano C，Oliva S，Martellossi S，et al.Pediatric gastrointestinal bleeding：perspectives from the italian society of pediatric gastroenterology[J].World JGastroenterol，2017，23（8）：1328-1337.
[8]	Ebrahimi BH，MortezaBagi HR，Rahmani F，et al.Clinical scoring systems in predicting the outcome of acute upper gastrointestinal bleeding：a narrative review[J].Emerg （Tehran），2017，5（1）：e36.
[9]	Oprita R，Oprita B，Diaconescu B，et al.Upper gastrointestinal endoscopy in emergency setting for patients receiving oral anticoagulants-practice updates[J].JMed Life，2017，10（1）：27-32.
[10]	Worden JC，Hanna KS.Optimizing proton pump inhibitor therapy for treatment of nonvariceal upper gastrointestinal bleeding[J].Am JHealth Syst Pharm，2017，74（3）：109-116.
[11]	Jiang M，Chen P，Gao Q.Systematic review and net-work meta-analysis of upper gastrointestinal hemorrhage interventions[J].Cell Physiol Biochem，2016，39（6）：2477-2491.
[12]	Loudin M，Anderson S，Schlansky B.Bleeding “downhill”esophageal varices associated with benign superior vena cava obstruction：case report and literature review[J].BMC Gastroenterol，2016，16（1）：134.
[13]	Garber A，Jang S.Novel therapeutic strategies in themanagement of non-variceal upper gastrointestinal bleeding[J].Clin Endosc，2016，49（5）：421-424.
[15]	VasapolliR，Malfertheiner P，Kandulski A.Helicobacter pylori and non-malignant upper gastrointestinal diseases[J].Helicobacter，2016，21（Suppl 1）：30-33.